The US subsidiary of pharmaceuticals and materials giant Bayer AG (or Bayer Group), Bayer Corporation operates through three divisions and an internal services company. Bayer Corporation handles Bayer Group's US operations in three segments: Bayer HealthCare (pharmaceuticals, animal health, and over-the-counter medicines), MaterialScience (plastics, coatings, and polyurethanes), and Bayer CropScience (herbicides, fungicides, and insecticides). The internal services unit, Bayer Corporate and Business Services, handles administrative, technology, human resources, legal, and procurement functions for the Bayer Group's US operations.

Pro-Pharmaceuticals, Inc. is a development-stage company engaged in the discovery and development of carbohydrate-based therapeutics. The Company’s therapeutics is used in treatment of liver, microbial and inflammatory diseases. All of its products were in development, including pre-clinical and clinical trials during the year ended December 31, 2008. The Company focuses on the development of a new generation of anti-cancer treatments using carbohydrate polymers to increase survival and improve the quality of life for cancer patients. Its principal pipeline candidate, DAVANAT, is a chemical entity that is in Phase II trials for first-line treatment of colorectal and biliary cancer. In September 2008, the Company submitted a clinical and pre-clinical package to the United States Food and Drug Administration (FDA) in support of its DAVANAT New Drug Application (NDA).

Simplexity Health (formerly Cell Tech International) hopes that the algae growing in the fountain of youth is the secret. More specifically, the company scrapes up Aphanizomenon flos-aquae, a type of blue-green algae, out of Upper Klamath Lake, and stirs it into nutritional supplements, body care products, and nutrition bars. Calling it Super Blue Green Algae, the company's product line includes digestive aids, weight loss supplements, antioxidants, and powdered drink mixes. Simplexity Health sells its products through a multi-level, direct marketing program using a network of independent associates.

The revolution in genomics and proteomics spawned by the human genome project is providing a steady stream of protein therapeutic candidates. Many of these proteins require enhancements in their pharmacokinetic properties in order to be clinically effective because of inherent limitations of proteins as drugs. Advanced Proteome Therapeutics has initiated a program that is broadly applicable to proteins. It builds on a technology platform developed over twenty years of targeting proteins for site-selective modification and addresses issues which limit therapeutic utilization of promising proteins.The Company’s laboratories are located at the BioSquare Innovation and Discovery Center on the campus of the Boston University School of Medicine. Its scientists are engaged in research and development applying leading edge chemical and biochemical methodologies to commercially viable proteins. The technology is applicable to the generation of a variety of protein products including protein therapeutics, protein diagnostics and high value reagents for research.

Cerep offers tools and knowledge to help those companies discover and develop new drugs without having to start from scratch. It also developed a library of compounds that includes promising substances and drug candidates developed with Bristol-Myers Squibb and Sanofi-Aventis. Customers use Cerep's expertise in compound profiling, computational chemistry, in vitro and in vivo pharmacology, and pharmacoinformatics to cut to the chase and develop successful drug candidates.

Alnylam Pharmaceuticals, Inc. company was founded in 2002 and is headquartered in Cambridge, Massachusetts. Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing therapeutics based on ribonucleic acid interference (RNAi). RNAi is a naturally occurring biological pathway within cells for selectively silencing and regulating the expression of specific genes. Its lead RNAi therapeutic program, ALN-RSV01, is in Phase II clinical trials for the treatment of human respiratory syncytial virus (RSV), infection. In February 2008, it reported positive results from its Phase II experimental RSV infection clinical trial, referred to as the GEMINI study. In April 2008, it initiated a second Phase II human clinical trial, which is, as of December 31, 2008, ongoing, to assess the safety and tolerability of aerosolized ALN-RSV01 versus placebo in adult lung transplant patients naturally infected with RSV. As of December 31, 2008, it formed collaborations with Cubist Pharmaceuticals, Inc. and Kyowa Hakko Kirin Co., Ltd., for the development and commercialization of products for RSV.

Allermed Laboratories, Inc. company was founded in 1971. Allermed Laboratories knows that in the case of allergies, a little bit of what caused the problem can be the solution. The company manufactures allergenic extracts, such as plant pollens, insects, fish and shellfish, and various foods, used to both diagnose and treat allergic conditions. The company is also developing additional skin tests for allergies, as well new tests to detect Leishmania parasite infections and exposure to the fungus Coccidioides immitis. Other products include empty test vials, vial trays, diluents, and extract mixing syringes. Outside of allergists' offices, the company provides environmental testing kits to detect mold contamination of buildings.

PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada. PDL BioPharma, Inc. engages in the management of antibody humanization patents and royalty assets, which consist of its Queen et al. patents and license agreements with various biotechnology and pharmaceutical companies. The company licenses its technologies to make and sell antibodies that bind to respiratory syncytial virus, as well as antibodies that bind to the alpha subunit of the VLA-4 integrin. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006.

BBI Holdings Plc, through its subsidiaries, engages in the development and manufacture of noninvasive lateral flow tests, and the distribution of diabetes products in the United Kingdom and internationally. It operates in three divisions: Diagnostics, Enzymes, and Healthcare. The Diagnostics division involves in the development, manufacture, supply of reagents. The Enzymes engages in the manufacturer and supply of specialist natural enzymes to the medical diagnostics industry. The Healthcare segment involves in the sale and marketing of GlucoGel, a dextrose gel used by diabetes patients when they experience hypoglycaemia; and development of diabetes care product portfolio. The company was founded in 1986 and is headquartered in Cardiff, the United Kingdom. As of February 12, 2008, BBI Holdings plc operates as a subsidiary of Inverness Medical Innovations Inc.

Pathwork Diagnostics is hoping to offer doctors the ability to predict which diseases a patient may have. The company is developing methods to identify biomarker patterns that indicate certain types of diseases. Many tests cannot identify diseases in their early forms. Pathwork Diagnostics is working on identifying the earliest possible signs of a given disease, such as cancer, to help doctors determine the best therapies to treat that disease. The company was founded in 2002. Investment firms Advent Venture, Prospect Venture, and Versant Ventures are the largest shareholders.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.